ozogamicin

出典: meddic


オゾガマイシン

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2014/07/17 14:17:17」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse.
  • Pilorge S1, Rigaudeau S, Rabian F, Sarkozy C, Taksin AL, Farhat H, Merabet F, Ghez S, Raggueneau V, Terré C, Garcia I, Renneville A, Preudhomme C, Castaigne S, Rousselot P.Author information 1Service d'Hématologie et d'Oncologie, Hôpital André Mignot, Le Chesnay, France.AbstractGemtuzumab ozogamicin (fGO), a humanized anti-CD33 monoclonal antibody linked to calicheamicin in combination with intensive chemotherapy gives high response rates in adult acute myeloid leukemia (AML) patients in relapse. However, reduced intensity chemotherapy in combination with fractionated GO has not been tested in aged relapsing patients. Patients from our institution with CD33+ AML aged 55 years or more in first late relapse (≥6 months) were proposed participation in a GO compassionate use program. Induction therapy consisted in fractionated GO (fGO; 3 mg/m(2) , days 1, 4, 7) with standard-dose cytarabine (200 mg/m(2) /day, 7 days). Patients were consolidated with two courses of GO and intermediate dose cytarabine. Twenty-four patients (median age 68 years) received fGO with cytarabine. Median follow-up was 42 months. The response rate was 75%, including complete remission (CR) in 16 patients and CR with incomplete platelet recovery (CRp) in two patients. Two-year overall survival (OS) was 51% (95% CI: 28-69) and 2 years relapse-free survival (RFS) was 51% (95%CI: 25-72). Duration of second CR (CR2) was longer than first CR (CR1) in 9 out of 18 patients. Minimal residual disease (MRD) was negative in evaluable patients in CR2, particularly in NPM1 mutated cases. Toxicity was in line with that of the same fractionated single agent GO schedule. Fractionated GO with low intensity chemotherapy produced high response rates and prolonged CR2 in aged AML patients in first late relapse. Am. J. Hematol. 89:399-403, 2014. © 2013 Wiley Periodicals, Inc.
  • American journal of hematology.Am J Hematol.2014 Apr;89(4):399-403. doi: 10.1002/ajh.23653. Epub 2014 Mar 7.
  • Gemtuzumab ozogamicin (fGO), a humanized anti-CD33 monoclonal antibody linked to calicheamicin in combination with intensive chemotherapy gives high response rates in adult acute myeloid leukemia (AML) patients in relapse. However, reduced intensity chemotherapy in combination with fractionated GO h
  • PMID 24375467
  • Novel targeted therapies in acute lymphoblastic leukemia.
  • Portell CA1, Advani AS.Author information 1Division of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic , Cleveland, OH , USA.AbstractAbstract Chemotherapy alone cures only 25-45% of adult patients with acute lymphoblastic leukemia (ALL), making novel treatment agents and strategies desperately needed. The addition of monoclonal antibodies (rituximab, alemtuzumab, epratzumab) to chemotherapy has demonstrated encouraging results in patients with newly diagnosed and relapsed ALL. The anti-CD22 immunoconjugate, inotuzumab ozogamicin, and the anti-CD19 BiTE(®) antibody, blinatumomab, have demonstrated impressive single agent activity in patients with relapsed or refractory B-ALL. Early reports of chimeric antigen receptor therapies have been promising in patients with relapsed ALL. Other agents targeting NOTCH1, FLT3, the proteasome and DNA methylation are early in development. These new agents hope to improve the outcome of ALL therapy with less toxicity. The challenge going forward will be to find safe and effective combinations and determine where in the treatment schema these agents will be most effective in ALL therapy.
  • Leukemia & lymphoma.Leuk Lymphoma.2014 Apr;55(4):737-48. doi: 10.3109/10428194.2013.823493. Epub 2013 Aug 28.
  • Abstract Chemotherapy alone cures only 25-45% of adult patients with acute lymphoblastic leukemia (ALL), making novel treatment agents and strategies desperately needed. The addition of monoclonal antibodies (rituximab, alemtuzumab, epratzumab) to chemotherapy has demonstrated encouraging results in
  • PMID 23841506
  • Novel Antibody Therapy in Acute Lymphoblastic Leukemia.
  • Kochuparambil ST1, Litzow MR.Author information 1Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA, kochuparambil.samith@mayo.edu.AbstractThe treatment of adult acute lymphoblastic leukemia (ALL) poses a tremendous challenge for hematologists. The use of pediatric-based chemotherapy regimens in young adults up to the age of 45 years has resulted in improved outcomes when compared retrospectively with historical controls treated with adult therapy. A better understanding of the molecular landscape of ALL and advances in the field of monoclonal antibody therapy have resulted in the development of several new agents that may provide for a reduction in the toxicity inherent in pediatric-like regimens. The anti-CD20 antibody, rituximab, anti CD22 antibody, epratuzumab, anti-CD22 antibody-drug conjugate, Inotuzumab ozogamicin, the bi-specific T-cell engager (BiTE) antibody, Blinatumomab, and chimeric receptor antigen (CAR) therapy are among the emerging agents that have demonstrated the potential to improve response rate and decrease toxicity when used alone or in combination with chemotherapy. Several role-defining phase II and phase III clinical trials with these agents are currently underway in the relapsed/refractory and newly diagnosed ALL settings.
  • Current hematologic malignancy reports.Curr Hematol Malig Rep.2014 Mar 13. [Epub ahead of print]
  • The treatment of adult acute lymphoblastic leukemia (ALL) poses a tremendous challenge for hematologists. The use of pediatric-based chemotherapy regimens in young adults up to the age of 45 years has resulted in improved outcomes when compared retrospectively with historical controls treated with
  • PMID 24623281

和文文献

  • Pulmonary veno-occlusive disease following reduced-intensity allogeneic bone marrow transplantation for acute myeloid leukemia
  • Hosokawa Kohei,Yamazaki Hirohito,Nishitsuji Masaru,Kobayashi Satoshi,Takami Akiyoshi,Fujimura Masaki,Nakao Shinji
  • Internal Medicine 51(2), 195-198, 2012
  • … We report a case of pulmonary veno-occlusive disease (PVOD) following allogeneic bone marrow transplantation (BMT) for the treatment of acute myeloid leukemia (AML) from an HLA mismatched mother using a reduced-intensity conditioning (RIC) regimen including gemtuzumab ozogamicin. …
  • NAID 120003989037
  • AML治療におけるゲムツズマブ・オゾガミシン : 最近の動向

関連リンク

癌,がん,ガン,化学療法,がん情報,放射線治療,米国国立がん研究所,抗がん剤 ... 【リニューアルのお知らせ】 「海外癌医療情報リファレンス」のウェブサイトは、2011年5月24日に全面リニューアルを行い、新サイトへ引越しました。
このページは、ファイザー株式会社の公式ホームページです。 ... 米ニューヨーク州ニューヨーク発、2013年5月20日 ― ファイザー社は、本日、治験薬inotuzumab ozogamicinの安全性および有効性を評価する2群からなる無作為化、非盲検第 ...

関連画像


押しても画像が表示されない場合はサーバが混雑しています。2週間ほどあけて、再度押下してください。


★リンクテーブル★
拡張検索inotuzumab ozogamicin

inotuzumab ozogamicin」

  [★]

イノツズマブオゾガマイシンイノツズマブ・オゾガマイシンイノツズマブオゾガミシン




★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡